MANGOCEUTICALS, INC. Files 8-K: Agreements, Equity Sales, Officer Changes
Ticker: MGRX · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 11 min |
| Key Dollar Amounts | $0.0001, $150,000, $1.50, $10,000, $500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, officer-changes
TL;DR
MANGOCEUTICALS filed an 8-K detailing new deals, stock sales, and exec changes. Watch closely.
AI Summary
On January 15, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and changes in its board and officer composition, including compensatory arrangements. The filing covers other events and includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions including new agreements and potential equity dilution, which could impact investor decisions.
Risk Assessment
Risk Level: medium — The filing mentions material definitive agreements and unregistered sales of equity securities, which can introduce financial and operational risks.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- January 15, 2025 (date) — Date of Earliest Event Reported
- 001-41615 (company) — SEC File Number
- 87-3841292 (company) — IRS Employer Identification No.
- 15110 N. Dallas Parkway , Suite 600 Dallas , Texas 75248 (company) — Principal Executive Office Address
FAQ
What type of material definitive agreement did MANGOCEUTICALS, INC. enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is January 15, 2025.
What are the key items disclosed in this 8-K filing?
The key items disclosed are entry into a material definitive agreement, unregistered sales of equity securities, departure/election of directors or officers, compensatory arrangements, other events, and financial statements/exhibits.
Where is MANGOCEUTICALS, INC. incorporated and what is its principal executive office address?
MANGOCEUTICALS, INC. is incorporated in Texas and its principal executive office is located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What is the SEC file number and IRS Employer Identification Number for MANGOCEUTICALS, INC.?
The SEC file number is 001-41615 and the IRS Employer Identification Number is 87-3841292.
Filing Stats: 2,761 words · 11 min read · ~9 pages · Grade level 11.6 · Accepted 2025-01-21 16:30:15
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $150,000 — . (" Mill End "), which entity was owed $150,000 from the Company pursuant to that certa
- $1.50 — based on an agreed conversion price of $1.50 per share. Pursuant to the Debt Conve
- $10,000 — greement, the Company agreed to pay him $10,000 per month. Pursuant to the Isaac Cons
- $500 — e-approval for any expense greater than $500. The Isaac Consulting Agreement may b
- $250,000 — he " Final Fourth Closing Shares ") for $250,000 in connection with a partial and final
- $1,100 — ck each have an initial stated value of $1,100 per share, and as a result, the effecti
- $2.59 — stock with exercise prices from between $2.59 and $2.71 per share); and those certain
- $2.71 — exercise prices from between $2.59 and $2.71 per share); and those certain common st
- $2.53 — with the SPA (with an exercise price of $2.53 per share), were automatically re-price
Filing Documents
- form8-k.htm (8-K) — 73KB
- ex10-1.htm (EX-10.1) — 50KB
- ex10-2.htm (EX-10.2) — 70KB
- 0001493152-25-003054.txt ( ) — 400KB
- mgrx-20250115.xsd (EX-101.SCH) — 3KB
- mgrx-20250115_lab.xml (EX-101.LAB) — 33KB
- mgrx-20250115_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01 by reference in its entirety
Item 1.01 by reference in its entirety. Consulting Agreement In connection with the appointment of Mr. Antonios Isaac as a member of the Board of Directors of the Company and as President of the Company, as discussed in greater detail in Item 5.02 , below, the Company entered into a Consulting Agreement with Mr. Isaac on January 15, 2025 (the " Isaac Consulting Agreement "). Pursuant to the Isaac Consulting Agreement, Mr. Isaac agreed to serve as the President of the Company and to provide services to the Company as reasonably requested during the term of the Isaac Consulting Agreement, which is 12 months. As consideration for the services to be provided by Mr. Isaac under the Isaac Consulting Agreement, the Company agreed to pay him $10,000 per month. Pursuant to the Isaac Consulting Agreement, we agreed to reimburse Mr. Isaac's expenses, subject to pre-approval for any expense greater than $500. The Isaac Consulting Agreement may be terminated prior to the end of the term (i) with the mutual approval of the parties; (ii) with written notice by the non-breaching party, upon the breach of the agreement by the other party, and the failure to cure such breach within 30 days; or (iii) by Mr. Isaac, at any time, for any reason. The Company may also terminate Mr. Isaac's position as President of the Company at any time, for any reason, which shall not operate as a termination of the Isaac Consulting Agreement, but shall only result in a termination of Mr. Isaac's role as President of the Company. The Company may also immediately terminate the Isaac Consulting Agreement for Cause upon written notice of termination to Mr. Isaac, with the particular Cause being specified in such notice. With respect to a termination by the Company, " Cause " means any of the following in the Company's reasonable judgment: (i) Mr. Isaac's act or acts amounting to gross negligence or willful misconduct to the detriment of the Company; (ii) Mr. Isaac's fraud or embezzlement of funds
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: January 21, 2025 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer